In a year heavily marked by the COVID-19 pandemic, the EIB Group confirmed its strong support to the Polish economy, providing
€5.2 billion of overall financing to the country’s public and private sectors. Volumes delivered in 2020 were largely in line with the trend of the previous years, a sign that the country responded swiftly to the pandemic and continued to invest in the future despite the forced downturn.
Loans granted by the European Investment Bank (EIB) amounted to
€4.6 billion, while the European Investment Fund (EIF) provided
€660 million in guarantees and equity investments to small and medium-sized businesses and mid-caps. In absolute terms, Poland was the fifth biggest recipient of EIB Group financing among the 27 EU Member States after Italy, France, Spain and Germany.
The EIB signed new loans amounting to €148 million and the EIF committed around €63 million in four equity and guarantee operations, benefiting a total of 2 600 businesses and supporting 25 000 jobs.
EIB Group provided €530m in loans, equity and guarantees to Croatia in 2020
The EIF contributed to the local economy to the tune of €187.9 million, making 2020 a record year for the EIF in Croatia. EIB | Zagreb | Updated: 26-02-2021 17:05 IST | Created: 26-02-2021 17:05 IST
Croatian companies, start-ups, SMEs and mid-caps alike will benefit from new venture capital funds launched through EIF cooperation with HBOR. Image Credit: Flickr
The European Investment Bank Group (EIB Group) provided €530 million in loans, equity and guarantees to clients in Croatia in 2020. The two parts of the EIB Group, the European Investment Bank (EIB) and the European Investment Fund (EIF), invested €342.5 million and €187.9 million, respectively, making 2020 a record year for the EIF in Croatia.
(2)
These two appointments follow a series of first successful achievements for iBiopsy in 2020 and early 2021.
Median prepares to launch its iBiopsy product development plan, including regulatory aspects, define its go-to-market strategy then expand its iBiopsy operations globally.
Regulatory News:
Thomas Bonnefont (Photo: Median Technologies)
Median Technologies (ALMDT:PA) (Paris:ALMDT) announced today the appointment of Thomas Bonnefont to the newly created position of Chief Operating and Commercial Officer of the iBiopsy Business Unit as well as the appointment of Mike Doherty as Sr. Strategy Advisor, iBiopsy Product Development. They both join Median s executive team. Mike Doherty is based in the US.
(1)
Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions.
The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide.
First results for a proof of concept on a cohort of 1,800 patients are expected in H2, 2021.
Regulatory News:
Median Technologies (ALMDT:PA) (Paris:ALMDT) unveils today a new iBiopsy Clinical Development Plan (CDP) for the diagnosis of early-stage lung cancer in high-risk populations based on Low Dose Computed Tomography (LDCT) scans, strengthening its positioning in early-stage diagnosis, such as early-stage liver cancer diagnosis and non-alcoholic steatohepatitis (NASH) identification.